Ola Grahn
Partner, Member of the Swedish Bar AssociationProfile
I have worked at corporate law firms since 2002, and I mainly work with company law, mergers and acquisitions and equity capital markets.
I am responsible for the corporate law, capital markets and M&A team at the Malmö office. I have particular experience from venture capital transactions, and assist both venture capital firms and entrepreneurs in conjunction with fundraisings. I also assist clients with equity capital markets and company law advice in connection with IPOs, new issues and incentive schemes. In addition to work within my specialist areas, I also provide advice on general corporate and commercial law matters to a number of clients within different industries. Within this area, I assist on the drafting, review and negotiation of a range of different commercial agreements such as distribution agreements and supply agreements. Since almost ten years, I have also lectured every semester on the in-depth course in company law at Lund University.
2003-,
Setterwalls
2002,
Advokatfirman Hammarskiöld & Co, Stockholm
2002,
Lund University, LL.M.
2002,
Lund University, B.Sc.
05 Feb 2025
Setterwalls advises Nordic Waterproofing in connection with recommended public takeover bid from Kingspan16 Jan 2025
Setterwalls advises Alligator Bioscience in connection with a rights issue of approximately SEK 280 million13 Sep 2024
Setterwalls advised Ascelia Pharma in connection with a fully subscribed rights issue of units26 Mar 2024
Setterwalls advises Alligator Bioscience in connection with rights issue of approximately SEK 150 million18 Mar 2024
Setterwalls has advised Asgard Therapeutics AB in connection with a EUR 30 million Series A financing06 Feb 2024
Setterwalls advises Nordic Waterproofing in connection with the public takeover bid from Kingspan17 Nov 2023
Setterwalls has assisted Better Collective in connection with cross-listing on Nasdaq Copenhagen19 Oct 2023
Setterwalls has assisted SynAct Pharma in connection with a private placement of SEK 60.5 million24 Nov 2022
Setterwalls has advised InCoax Networks in connection with rights issue and over-allotment25 May 2022
Setterwalls has advised Trill Impact in connection with a private placement in Cinclus Pharma11 Oct 2021
Setterwalls has assisted 2150 and ETF Partners in connection with investment in Normative06 Jul 2021
Setterwalls has advised Amniotics AB (publ) in connection with listing on Nasdaq First North Growth Market28 Jun 2021
Setterwalls advises Linkfire A/S in connection with listing on Nasdaq First North Premier Growth Market21 Jun 2021
Setterwalls advises USWE Sports AB in connection with listing on Nasdaq First North Growth Market27 May 2021
Setterwalls assists Better Collective in connection with private placement of SEK 1.5 billion08 Feb 2021
Setterwalls has advised SynAct Pharma in connection with SEK 80 million private placement28 Jan 2021
Setterwalls has advised Alligator Bioscience in connection with over-subscribed rights issue11 Jan 2021
Setterwalls has assisted Polygiene in connection with private placement and the acquisition of Addmaster06 Nov 2020
Setterwalls advises inRiver in connection with private placement of approximately SEK 285 million23 Oct 2020
Setterwalls advised Alelion Energy Systems AB in connection with oversubscribed rights issue06 Oct 2020
Setterwalls has advised Guard Therapeutics in connection with rights issue and over-allotment17 Sep 2020
Setterwalls advises the majority shareholders in connection with sale of shares in Better Collective10 Sep 2020
Setterwalls has advised InCoax Networks AB in connection with an oversubscribed rights issue11 Aug 2020
Setterwalls advises Saniona in connection with directed issue of approximately SEK 567 million10 Jul 2020
Setterwalls has advised Advenica in connection with a substantially oversubscribed rights issue01 Jul 2020
Setterwalls advises Ascelia Pharma in connection with SEK 98.7 million private placement27 May 2020
Setterwalls has advised BONESUPPORT in connection with SEK 378 million private placement04 Mar 2020
Setterwalls advises Qlife Holding AB in connection with the listing on Nasdaq First North Growth Market04 Dec 2019
Setterwalls advises Better Collective in connection with SEK 312 million private placement25 Jun 2019
Setterwalls has advised RhoVac in connection with a rights issue of approximately SEK 180.9 million13 Mar 2019
Setterwalls has assisted Ascelia Pharma in this year’s first listing at Nasdaq Stockholm23 Nov 2016
Setterwalls assists Alligator Bioscience AB in connection with listing on Nasdaq Stockholm11 Mar 2016
Setterwalls assist in connection with the Private Placement in Nexam Chemical Holding AB (publ29 Jan 2016
Setterwalls has assisted Enzymatica AB (publ) in the acquisition of the Icelandic company Zymetech07 Oct 2015
Setterwalls assisted KLS Ugglarps in the acquisition of the majority shares in Dalsjöfors Kött07 Aug 2015
Setterwalls has assisted Arise AB (publ) in the sale of the wind farm Mombyåsen to Allianz Capital Partners10 Jun 2014
Setterwalls assists LIDDS in connection with fundraising and listing on NASDAQ OMX First North14 Mar 2014
Setterwalls acted as legal advisors in connection with Private Placement in Nexam Chemical Holding AB25 Feb 2011
Midsona Group AB chooses Setterwalls20 Aug 2014
M&A Report August 2014”Ola Grahn is highly experienced, and delivered very strong and speedy support for us.”
Legal 500
”The lead partner Ola Grahn can grasp many different angles/disciplines and not solely related to capital markets. That provides us with a good foundation for making robust decisions and the potential consequences of these decisions. ”
Legal 500
”Ola Grahn stands out for the ability to see beyond the strict legal aspects to have a solid understanding of our business.”
Legal 500
”Ola Grahn exhibits valuable insights into explaining and understanding the long-term consequences of legal decisions.”
Legal 500
”Always available. He has a great understanding of how a multinational high-growth startup operates.”
IFLR1000
”Highly experienced, good communications skills, pragmatic, and has broad competence.”
IFLR1000